PRESS RELEASE published on 06/25/2025 at 07:00, 1 year 1 month ago Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Sanofi's riliprubart granted orphan drug designation by FDA for antibody-mediated rejection in solid organ transplantation, addressing critical unmet need in transplant medicine Orphan Drug Designation Sanofi Riliprubart Antibody-mediated Rejection Solid Organ Transplantation
PRESS RELEASE published on 06/24/2025 at 04:36, 1 year 1 month ago Sanofi : Déclaration des transactions sur actions propres
BRIEF published on 06/23/2025 at 07:05, 1 year 1 month ago Sarclisa Gains EU Recommendation for Multiple Myeloma Treatment Multiple Myeloma Phase 3 Study Sarclisa CHMP Approval Induction Therapy
BRIEF published on 06/23/2025 at 07:05, 1 year 1 month ago Sarclisa obtient une recommandation de l'UE pour le traitement du myélome multiple Myélome Multiple Étude De Phase 3 Sarclisa Approbation Du CHMP Thérapie D'induction
PRESS RELEASE published on 06/23/2025 at 07:00, 1 year 1 month ago Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Sarclisa recommended for EU approval by CHMP for transplant-eligible newly diagnosed multiple myeloma based on GMMG-HD7 study. Potential to improve outcomes in frontline setting globally Multiple Myeloma Sarclisa EU Approval GMMG-HD7 Study CHMP Recommendation
PRESS RELEASE published on 06/23/2025 at 07:00, 1 year 1 month ago Communiqué de presse : Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple. Recommandation basée sur l'étude de phase 3 GMMG-HD7 montrant amélioration significative de la SSP Myélome Multiple Approbation Sarclisa CHMP GMMG-HD7
BRIEF published on 06/20/2025 at 07:05, 1 year 1 month ago FDA Approves Dupixent for Bullous Pemphigoid Treatment FDA Approval Dupixent Type 2 Inflammation Bullous Pemphigoid Rare Skin Disease
BRIEF published on 06/20/2025 at 07:05, 1 year 1 month ago La FDA approuve le Dupixent pour le traitement de la pemphigoïde bulleuse Approbation De La FDA Dupixent Pemphigoïde Bulleuse Inflammation De Type 2 Maladie Cutanée Rare
PRESS RELEASE published on 06/20/2025 at 07:00, 1 year 1 month ago Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Dupixent approved in the US as the only targeted medicine for bullous pemphigoid, meeting the critical treatment needs of patients with uncontrolled disease FDA Approval Chronic Disease Dupixent Type 2 Inflammation Bullous Pemphigoid
PRESS RELEASE published on 06/20/2025 at 07:00, 1 year 1 month ago Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse Dupixent approuvé par la FDA aux États-Unis pour traiter la pemphigoïde bulleuse, offrant une nouvelle approche ciblée contre l'inflammation de type 2. Résultats positifs de l'étude ADEPT FDA Dupixent Pemphigoïde Bulleuse Inflammation De Type 2 Étude ADEPT
Published on 08/03/2026 at 23:00, 4 hours 49 minutes ago Viemed Healthcare Announces Second Quarter 2026 Financial Results
Published on 08/01/2026 at 01:58, 3 days 1 hour ago Clôture de l'option sur la propriété de graphite au Québec
Published on 08/01/2026 at 01:20, 3 days 2 hours ago Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 3 days 2 hours ago Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 3 days 3 hours ago Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 08/03/2026 at 23:33, 4 hours 15 minutes ago EQS-Adhoc: Verbio SE: Preliminary EBITDA for FY 2025/2026 exceeds forecast
Published on 08/03/2026 at 23:20, 4 hours 28 minutes ago DeFi Technologies Announces Shareholder Call to Discuss Q2 2026 Financial Results
Published on 08/03/2026 at 21:39, 6 hours 9 minutes ago PAUL Tech AG reports net income after tax of EUR 3.2 million for fiscal year 2025 and issues a positive outlook for fiscal year 2026
Published on 08/03/2026 at 19:35, 8 hours 13 minutes ago Enzene Launches NeX™, a Comprehensive Suite of Solutionsto Enable Cost-Efficient, High-Yielding Local Biomanufacturing
Published on 08/03/2026 at 19:01, 8 hours 48 minutes ago EQS-Adhoc: Fresenius Medical Care AG : Fresenius Medical Care reports operating income excluding special items to be above market expectations in Q2 2026 and confirms its outlook for the financial year 2026
Published on 08/03/2026 at 18:45, 9 hours 4 minutes ago Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 08/03/2026 at 18:45, 9 hours 4 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 08/03/2026 at 18:35, 9 hours 14 minutes ago Covivio Hotels - Informations relatives au nombre total de droits de vote et d'actions composant le capital social